Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.47 |
| ▸ | BTK | Q06187 | 9/20 | 0.44 |
| ▸ | PLCG1 | P19174 | 4/20 | 0.43 |
| ▸ | ITK | Q08881 | 3/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | BLK | P51451 | 1/20 | 0.39 |
| ▸ | BMX | P51813 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24150645 | 1.00 | JAK3 (0.47) | JAK3BTKPLCG1ITKGAK | |
| SCHEMBL24151431 | 0.86 | JAK3 (0.49) | JAK3BTKPLCG1ITKGAK | |
| SCHEMBL30190511 | 0.86 | JAK3 (0.49) | JAK3BTKPLCG1ITKGAK | |
| SCHEMBL30190762 | 0.85 | JAK3 (0.48) | JAK3BTKPLCG1ITKGAK | |
| SCHEMBL24151400 | 0.85 | JAK3 (0.48) | JAK3BTKPLCG1ITKGAK | |
| SCHEMBL24150184 | 0.82 | JAK3 (0.54) | JAK3BTKPLCG1ITKGAK | |
| SCHEMBL30190830 | 0.82 | JAK3 (0.54) | JAK3BTKPLCG1ITKGAK | |
| SCHEMBL24150523 | 0.81 | JAK3 (0.57) | JAK3BTKPLCG1ITKGAK | |
| SCHEMBL24150173 | 0.80 | JAK3 (0.56) | JAK3BTKPLCG1ITKGAK | |
| SCHEMBL24150378 | 0.80 | BRAF (0.52) | JAK3BTKPLCG1EGFRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | JAK3 4427/4885BTK 4194/4885PLCG1 2034/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | JAK3 4427/4885BTK 4194/4885PLCG1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.